GSWM
SMMT icon

Golden State Wealth Management’s Summit Therapeutics SMMT Stock Holding History

Golden State Wealth Management’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$12.1K Hold
828
– – ﹤0.01% 1075
2026
Q1 		$15.7K Hold
828
– – ﹤0.01% 976
2025
Q4 		$14.5K Hold
828
– – ﹤0.01% 1005
2025
Q3 		$17.1K Hold
828
– – ﹤0.01% 950
2025
Q2 		$17.6K Buy
828
+77
+10% +$1.76K ﹤0.01% 922
2025
Q1 		$14.5K Hold
751
– – ﹤0.01% 896
2024
Q4 		$13.4K Buy
+751
New +$14.6K ﹤0.01% 875

Other funds holding SMMT

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Golden State Wealth Management's SMMT Position: Q2 2026 in Review

Golden State Wealth Management held its Summit Therapeutics (SMMT) position steady in Q2 2026 at 828 shares worth $12.1K. The position accounts for ﹤0.01% of the portfolio, ranked #1075.

Golden State Wealth Management first reported a position in SMMT in Q4 2024 and has held it in 7 quarters since. The position peaked at $17.6K in Q2 2025. 242 funds tracked by Wall St. Rank hold SMMT as of Q2 2026.

  • Golden State Wealth Management held 828 shares of Summit Therapeutics worth $12.1K as of Q2 2026.
  • Golden State Wealth Management left its Summit Therapeutics share count unchanged in Q2 2026.
  • Summit Therapeutics made up ﹤0.01% of Golden State Wealth Management's portfolio in Q2 2026, its #1075 holding.
  • Golden State Wealth Management first reported a position in Summit Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • Golden State Wealth Management's Summit Therapeutics position peaked at $17.6K in Q2 2025.
  • 242 funds tracked by Wall St. Rank held Summit Therapeutics as of Q2 2026.

Based on Golden State Wealth Management's 13F filing for Q2 2026, filed 22 Jul 2026.